Rheumatology
Latest News
Autoimmune Skin Diseases Linked To Risk Of Adverse Pregnancy Outcomes
The three most common autoimmune skin diseases in the study cohort were vitiligo (30%), alopecia areata (30%), and cutaneous lupus erythematosus (...
From the Journals
COVID vaccination protects B cell–deficient patients through T-cell responses
The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write.
Latest News
Rheumatology Match Day results for 2024 follow trends of past years
Adult rheumatology remains popular, but pediatric rheumatology continues to be less successful, filling only 55% of programs.
From the Journals
Low-dose methotrexate carries higher risk for older patients with CKD
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
Guidelines
Conditional recommendations rule in new SARD-associated interstitial lung disease guidelines
“Clinicians must retain the latitude to prescribe medications based on individual patient factors and preferences.”
Conference Coverage
Abatacept reduced rates of progression to RA, phase 2b trial finds
The study was conducted at 28 sites in the United Kingdom and 3 in The Netherlands.
Conference Coverage
Telitacicept shows efficacy, safety in methotrexate-resistant RA
The investigational drug’s ACR 20 response rate was typical for RA biologic treatments, and the trial’s Chinese patient population didn’t include...
Feature
Cold-water swimming for your health? These docs say jump in
“All you need is some water – enough to submerge your entire body in – that’s less than 68 °F (20 °C).”
Conference Coverage
Novel blood test can detect RA
An experimental assay detects epigenetic features within the unique patterns and sizes of cell-free DNA found in blood, but is it better than...
Conference Coverage
Split-dose methotrexate speeds RA response over single dose
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs,...
Conference Coverage
IV secukinumab, alternative to self-injections, reaches primary endpoints in PsA, axSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and...